Verrica Pharmaceuticals Inc (VRCA NASDAQ) stock market data APIs
$4.7706
0.25(5.2%)
as of September 12, 2025
Try our APIs with
free plan!
Verrica Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Prev. Close
4.7706
Open
5.0204
High
5.0204
Low
4.7049
52 wk Range
3.816-20.127
Market Cap
44 867 K
Shares Outstanding
9 446 K
Revenue
14 704 K
EPS
0.02
Beta
1.787
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Verrica Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Verrica Pharmaceuticals Inc data using free add-ons & libraries
Get Verrica Pharmaceuticals Inc Fundamental Data
Verrica Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 14 704 K
- EBITDA: -37 150 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Verrica Pharmaceuticals Inc News
New
Verrica Pharmaceuticals Non-GAAP EPS of $0.25 beats by $1.08, revenue of $12.7M
* Verrica Pharmaceuticals press release [https://seekingalpha.com/pr/20198555-verrica-pharmaceuticals-reports-second-quarter-2025-financial-results] (NASDAQ:VRCA [https://seekingalpha.com/symbol/VRC...
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
– Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in mileston...
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
Soleno Therapeutics, Inc. (SLNO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.57 per share a year ago. These ...
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for s...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
